Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi) target tumours defective in homologous recombination (HR). Most BRCA-wild-type (WT) HR-proficient breast cancers are intrinsically resistant to PARP inhibitors, e.g., talazoparib. We evaluated the role of autophagy in this de novo resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai Bellare, Ganesh, Saha, Bhaskar, Patro, Birija Sankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007595/
https://www.ncbi.nlm.nih.gov/pubmed/33473172
http://dx.doi.org/10.1038/s41416-020-01238-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007595/
https://www.ncbi.nlm.nih.gov/pubmed/33473172
http://dx.doi.org/10.1038/s41416-020-01238-0

Ejemplares similares